Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Buy” from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has earned an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $107.00.

A number of equities analysts have recently weighed in on the stock. Morgan Stanley began coverage on shares of Monopar Therapeutics in a research note on Friday, January 9th. They set an “overweight” rating and a $115.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday. Wall Street Zen cut shares of Monopar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, April 11th. Finally, BTIG Research reiterated a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a research report on Monday, February 23rd.

Monopar Therapeutics Price Performance

MNPR opened at $53.24 on Friday. Monopar Therapeutics has a 12 month low of $28.40 and a 12 month high of $105.00. The stock has a market capitalization of $356.18 million, a P/E ratio of -29.25 and a beta of 1.64. The business has a 50 day simple moving average of $55.98 and a 200-day simple moving average of $68.93.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.10). Research analysts anticipate that Monopar Therapeutics will post -4.31 EPS for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ally Bridge Group NY LLC boosted its position in Monopar Therapeutics by 86.6% during the third quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after purchasing an additional 29,918 shares in the last quarter. AlphaQuest LLC increased its position in shares of Monopar Therapeutics by 8.5% in the third quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after buying an additional 151 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Monopar Therapeutics in the second quarter valued at $209,000. TD Asset Management Inc acquired a new position in shares of Monopar Therapeutics during the 4th quarter worth $201,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Monopar Therapeutics in the 2nd quarter worth about $104,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.